Key financial metrics, growth trends, and downloadable reports
| Financial Year | Report Type | Published Date | Action |
|---|---|---|---|
| 2026 | Annual Report | 31/12/2026 | Not Available |
Macleods Pharma Shares is an unlisted company with limited publicly available financial data. Below are the key financial metrics available for analysis.
Note: As Macleods Pharma Shares is an unlisted company, detailed year-by-year financial data may not be publicly available. The data provided above represents the most recent available financial information.
Above N/A average
Excellent return on shareholder equity
Very low leverage
Significant premium to book value
Currently trading near 52-week low
Macleods Pharma Shares's financial ratios highlight its market position in the N/A sector, though direct peer comparisons may vary based on its business model. The Price-to-Earnings (P/E) ratio of ₹24.6 indicates investors have high growth expectations, reflecting market confidence in the company's brand and business performance. The Return on Equity (ROE) of 23.96 shows very efficient use of shareholder funds to generate profits, signaling strong management performance.
Macleods Pharma Shares's Debt-to-Equity ratio of 0.0184 demonstrates a very conservative financial approach, reducing financial risk. Meanwhile, the Price-to-Book (P/B) ratio of 6.85 suggests the market places a high premium on the company's assets, anticipating future revenue growth and continued business performance. These metrics collectively position Macleods Pharma Shares as a premium investment with strong growth potential and good financial stability within its sector.
Get expert guidance on Macleods Pharma Shares investment potential based on its financial performance.
Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.
The minimum investment for Macleods Pharma Shares typically depends on the current market price. With a share price of ₹505, we recommend contacting us for the latest details on minimum investment requirements.
Yes, KYC (Know Your Customer) is mandatory for all unlisted share transactions in India. This is a regulatory requirement to prevent money laundering and ensure legitimate transactions. You&ll need to provide identity proof, address proof, PAN card, and bank details.
Once all documentation is complete and verified, the transaction typically takes 2-3 business days for processing and settlement. The shares will be transferred to your demat account within this timeframe after payment confirmation.
Investing in unlisted shares involves certain risks including liquidity risk (difficulty in selling quickly), valuation uncertainty, limited regulatory oversight, and potential information asymmetry. However, they also offer the potential for higher returns especially if the company performs well or goes for an IPO.
Yes, Non-Resident Indians (NRIs) can invest in unlisted shares in India through the Portfolio Investment Scheme (PIS). However, they need to comply with FEMA regulations and may require special permissions. NRIs should consult with their financial advisors regarding the specific requirements.
You can track your Macleods Pharma Shares unlisted shares through our portfolio tracking service. We provide regular updates on significant developments, valuation changes, and other important information related to Macleods Pharma Shares and other unlisted companies in your portfolio.
